FN2 Earnings Intelligence

Kymera Therapeutics, Inc. earnings overview

Latest Kymera Therapeutics, Inc. (KYMR) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportKymera Therapeutics, Inc. reports Thursday, Feb 25, 2027 · Before market openConsensus EPS $-1.27 · consensus revenue $2.0M
KYMR FY2026 Q3 · Calendar Q4 2026

Kymera Therapeutics, Inc.

Kymera's latest update strengthens the clinical-pipeline case through progress for KT-621 and KT-579, but the investment narrative still depends on pending patient data and successful execution of later-stage studies.

EPS surprise—
Market move+0.1%

Get the KYMR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.